Morgan Stanley raised its price target on Biogen (NASDAQ: BIIB) to $369.00 (from $365.00) while maintaining a Overweight rating.

Analyst PT Change

Biogen (BIIB) PT Lowered to $272 at Cantor FitzgeraldApril 26, 2018 1:49 AM Biogen (BIIB) PT Lowered to $311 at RBC CapitalApril 25, 2018 7:43 AM Biogen (BIIB) PT Lowered to $375 at OppenheimerApril 25, 2018 7:15 AM Biogen (BIIB) PT Lowered to $325 at Leerink PartnersApril 25, 2018 6:37 AM Biogen (BIIB) PT Lowered to $385 at GuggenheimApril 25, 2018 2:03 AM UPDATE: Baird Upgrades Biogen (BIIB) to OutperformApril 25, 2018 1:08 AM UPDATE: Goldman Sachs Downgrades Biogen (BIIB) to BuyApril 25, 2018 12:56 AM Biogen (BIIB) PT Lowered to $353 at Piper JaffrayApril 24, 2018 1:30 PM